Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TriGenix offers a third option to the sales dilemma

TriGenix offers a third option to the sales dilemma

TriGenix Inc. has been formed with $6 million from D. Blech & Co. Inc. to take advantage of what it sees as an up-and-coming opportunity to provide biotech companies with sales, marketing and reimbursement services.

According to Don

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE